Re-examination of the Natural History of High-grade T1 Bladder Cancer using a Large Contemporary Cohort

Abstract

ARTICLE INFO ______________________________________________________________ ______________________Introduction: High-grade T1 (HGT1) bladder cancer represents a clinical challenge in that the urologist must balance the risk of disease progression against the morbidity and potential mortality of early radical cystectomy and urinary diversion. Using two non-muscle invasive bladder cancer (NMIBC) databases, we re-examined the rate of progression of HG T1 bladder cancer in our bladder cancer populations. Materials and Methods:We queried the NMIBC databases that have been established independently at the Atlanta Veterans Affairs Medical Center (AVAMC) and the University of Pennsylvania to identify patients initially diagnosed with HGT1 bladder cancer. Demographic, clinical, and pathologic variables were examined as well as rates of recurrence and progression.Results: A total of 222 patients were identified; 198 (89.1%) and 199 (89.6%) of whom were male and non-African American, respectively. Mean patient age was 66.5 years. 191 (86.0%) of the patients presented with isolated HG T1 disease while 31 (14.0%) patients presented with HGT1 disease and CIS. Induction BCG was utilized in 175 (78.8%) patients. Recurrence occurred in 112 (50.5%) patients with progression occurring in only 19 (8.6%) patients. At a mean follow-up of 51 months, overall survival was 76.6%. Fifty two patients died, of whom only 13 (25%) patient deaths were bladder cancer related. Conclusions: In our large cohort of patients, we found that the risk of progression at approximately four years was only 8.6%. While limited by its retrospective nature, this study could potentially serve as a starting point in re-examining the treatment algorithm for patients with HG T1 bladder cancer.

Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette–Guérin immunotherapy?

“…Consistent with other reports demonstrating 3-to 5-year recurrence rates below 51 % [4,[9][10][11][12] and progression rates below 23 % [10,12,13], our data showed 5-year recurrence and progression rates of 49.4 and 18.0 %, respectively. Interestingly, the present findings for short-and intermediate-term observations were inconsistent with the probability of tumour recurrence and progression calculated by the EORTC and CUETO scoring models [14,15].…”

ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update

“…In patients at high risk, 59.6% (2,694 of 4,521) of patients develop multiple recurrences within 2 years of initial treatment [34]. In addition, progression to MIBC is seen in 8.6% to 15% of patients with high-risk disease [35][36][37].…”

Cytokeratin 20 immunocytochemistry on urine sediments: A potential low‐cost adjunct to cytology in the diagnosis of low‐grade urothelial carcinoma

“…Although the disease is not lethal in the majority of cases, it is said to be the most expensive malignancy . The majority (70%) of these are low‐grade, non‐muscle invasive, papillary neoplasms amenable to local resection and intravesical chemotherapy; however, progression to muscle invasive disease and multiple recurrences may be seen in close to half of all patients . High tumour grade is an important determinant of disease progression …”